Mirum Pharmaceuticals Dividende
Zukünftiges Wachstum Kriterienprüfungen 0/6
Mirum Pharmaceuticals does not have a record of paying a dividend.
Wichtige Informationen
n/a
Dividendenausschüttung
-11.3%
Rückkaufsrendite
Gesamte Aktionärsrendite | -11.3% |
Zukünftige Dividendenrendite | 0% |
Wachstum der Dividende | n/a |
Nächster Dividendenzahlungstermin | n/a |
Ex-Dividendendatum | n/a |
Dividende pro Aktie | n/a |
Ausschüttungsquote | n/a |
Aktuelle Dividendenentwicklung
Keine Aktualisierungen
Recent updates
Is Mirum Pharmaceuticals (NASDAQ:MIRM) Using Too Much Debt?
Nov 03Mirum Pharmaceuticals: Intriguing, But Wait For Volixibat Data Makes Me Bearish
Oct 04Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition
Jul 17Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Fly 46% But Investors Aren't Buying For Growth
Jul 13Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Business And Shares Still Trailing The Industry
May 28Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value
Apr 22Mirum Pharmaceuticals: Advancing On Several Key Fronts
Mar 05There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price
Dec 26What Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) P/S Is Not Telling You
Jun 10Industry Analysts Just Made A Captivating Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts
Apr 18Mirum's liver disease drug Livmarli gets EMA committee nod for approval in EU
Oct 14Mirum: Great Sales Start For Livmarli Paves The Way For Long-Term Growth
Aug 17Mirum Pharmaceuticals announces $80M stock offering
Aug 09Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent
May 27Stabilität und Wachstum des Zahlungsverkehrs
Rufe Dividendendaten ab
Stabile Dividende: Insufficient data to determine if MIRM's dividends per share have been stable in the past.
Wachsende Dividende: Insufficient data to determine if MIRM's dividend payments have been increasing.
Dividendenrendite im Vergleich zum Markt
Mirum Pharmaceuticals Dividendenrendite im Vergleich zum Markt |
---|
Segment | Dividendenrendite |
---|---|
Unternehmen (MIRM) | n/a |
Untere 25 % des Marktes (US) | 1.5% |
Markt Top 25 % (US) | 4.5% |
Branchendurchschnitt (Biotechs) | 2.2% |
Analystenprognose (MIRM) (bis zu 3 Jahre) | 0% |
Bemerkenswerte Dividende: Unable to evaluate MIRM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Hohe Dividende: Unable to evaluate MIRM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Gewinnausschüttung an die Aktionäre
Abdeckung der Erträge: Insufficient data to calculate MIRM's payout ratio to determine if its dividend payments are covered by earnings.
Barausschüttung an die Aktionäre
Cashflow-Deckung: Unable to calculate sustainability of dividends as MIRM has not reported any payouts.